Terry Rosen, PhD
Chief Executive Officer
Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression…. Previously, Dr. Rosen was co-founder and CEO of Flexus Biosciences, focusing on small molecule drugs that reverse tumor immunosuppression. He has held several executive positions at Amgen and Tularik, as well as scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen also serves on the boards of scientific institutions such as the Salk Institute Board of Trustees and the Caltech Biology & Engineering Chair’s Council.
Juan Jaen, PhD
Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years, and in 2015 he co-founded Arcus. Before starting Arcus, Dr. Jaen was co-founder and President of Flexus Biosciences. He was Chief Scientific Officer and SVP of Drug Discovery at ChemoCentryx for 7 years…, where he led the discovery and progression into the clinic of 8 novel immunology drug candidates. Dr. Jaen has also held various positions at Amgen, Tularik, and Parke-Davis/Warner-Lambert. He is an inventor on 50 patents and has helped the advancement of over 20 novel molecules into clinical development across a range of indications.
Chief Operating Officer
Ms. Jarrett is an accomplished executive in the healthcare and technology industries. She most recently served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc., and prior to this, was Chief Operating Officer and Chief Financial Officer of Arcus Biosciences. Ms. Jarrett has been an ongoing member… of Arcus’s board of directors since January 2019. Prior to Arcus, Ms. Jarrett was Chief Financial Officer of Medivation, a commercial oncology company that developed XTANDI®️ (enzalutamide), which has become an established standard-of-care therapy for the treatment of prostate cancer. Ms. Jarrett spent 20 years in investment banking, including an extensive tenure at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Ms. Jarrett also serves on the boards of Syndax Pharmaceuticals and Arena Pharmaceuticals.
Chief Financial Officer
Mr. Goeltz has an extensive track record and breadth of experience in finance and accounting, most recently serving as Chief Financial Officer and Senior Vice President of UNITY Biotechnology and immediately before that as Chief Financial Officer of… CytomX Therapeutics, leading both of the companies’ IPOs and finance organizations. Prior to these positions, Mr. Goeltz had an 11-year tenure at Amgen, holding positions including the Chief Financial Officer of Onyx Pharmaceuticals after its acquisition by Amgen, and senior financial roles in commercial and R&D finance, business development and accounting. In his roles at Amgen, he was involved in multiple oncology product launches. Earlier in his career, he served as Director of Finance for Tularik. Mr. Goeltz began his career in the audit practice of EY. Mr. Goeltz received his Master of Business Administration degree from UCLA’s Anderson School of Management and his Bachelor of Business Administration degree from Emory University’s Goizueta School of Business.
Chief Commercial Officer
Mr. Matthews has more than 20 years of experience in biopharmaceuticals in roles spanning global product strategy, marketing, and product development as well as US marketing and sales leadership. Over his career, he has launched 15 new medicines, including Avastin®, Tarceva®, Tecentriq®, and Imfinzi®. … Prior to joining Arcus, Mr. Matthews was with AstraZeneca and Roche/Genentech where he worked on first-in-class immunotherapy products and novel therapeutic combinations. He has also worked as a Congressional Health Policy Analyst and was involved in developing the Medicare Modernization Act.
Dimitry S.A. Nuyten, MD, PhD
Chief Medical Officer
Dr. Nuyten is a physician-scientist with broad experience built over 15 years across all phases of drug development. He joined Arcus in August 2022 from Chief Medical Officer roles at Nektar Therapeutics and Aduro Biotech. …Until 2019, he was Vice President and Immuno-Oncology Development Leader at Pfizer, responsible for the full development program and registrational strategy for Bavencio® and the development of multiple immuno-oncology programs. Earlier in his career he led early development for immuno-oncology at Pfizer and served as Group Medical Director at Bristol-Myers Squibb in the early development oncology group. Dr. Nuyten received his M.D. from the University of Groningen and his Ph.D. from the University of Amsterdam. He trained as a radiation oncologist at the Netherlands Cancer Institute in Amsterdam and was a visiting scientist at Stanford University from 2004-2005.
Jonathan Yingling, PhD
Chief Scientific Officer
After several years as a member of the Arcus Scientific Advisory Board, in 2020 Jonathan joined Arcus as Senior Vice President, Research. As a member of the Research Leadership team, Jonathan provides guidance to all aspects of our research, discovery and translational efforts, creating a key research interface with our Development organization. …
Throughout Jonathan’s long tenure in the pharmaceutical/biotech industry, he has held senior leadership positions in the R&D organizations of several pillars of our sector, including BMS (VP, Oncology Discovery & Translational Research), and Lilly (VP Oncology Research and then VP Translational Science & Technology), as well as innovative biotech companies Idera Pharmaceuticals (CSO) and Bind Therapeutics (CSO). He has applied his extensive scientific expertise in oncology and translational research to the discovery and development of multiple cancer drugs. He also established and led global research and translational science partnerships in the U.S., Singapore, China and Europe. In addition, he championed and led major merger and acquisition transactions. Jonathan has been involved in the discovery and development of more than 15 drug candidates, including galunisertib and merestinib.
Jonathan earned his Ph.D. in Cell and Molecular Biology and Pharmacology at Duke University and was a Howard Hughes Postdoctoral Fellow at Vanderbilt University. He has co-authored 65 scientific papers and is listed as inventor in 2 issued US patents.
Carolyn Tang, JD
Ms. Tang is an attorney with broad expertise in transactions, intellectual property, securities, and corporate governance in the US and Europe. Prior to joining Arcus, she worked at Medivation as well as InterMune, where she oversaw InterMune’s global IP portfolio and supported… the approval and commercialization of Esbriet®. Ms. Tang also helped establish and administer InterMune’s European subsidiaries and assisted in public offerings and common stock before the company’s acquisition by Roche.
SVP, Regulatory and Quality
Patty Carlos has more than 20 years of experience in regulatory affairs leading activities across program lifecycles from investigational new drug application (IND) to commercialization. She joined Arcus in 2019 … from Bellicum Pharmaceuticals, where she served as Vice President and Global Head of Regulatory Affairs. Previously, Ms. Carlos held roles of increasing responsibility in regulatory affairs at BeiGene, Medivation, Gilead Sciences, Vifor Pharma and Bayer.
SVP, Human Resources
Yvonne Gehring is a seasoned Human Resources professional with more than 30 years of experience in the biopharmaceutical industry, specializing in talent management, organizational development, and compensation and benefits. … She joined Arcus in 2015 and currently serves as SVP, of human resources and operations. Prior to Arcus, she was head of human resources at ChemoCentryx, Inc. Previously, Ms. Gehring held roles with increasing responsibility in human resources at Theravance, Inhale, Systemix, and Genentech.
Jay Powers, PhD
SVP, Drug Discovery
Dr. Powers has a remarkable track record of success in drug discovery spanning 25 years. Most recently, Jay was VP of Drug Discovery at Flexus Biosciences and then FLX Bio. At Flexus he oversaw drug design efforts in the IDO inhibitor program before it was acquired by BMS. He was previously… at ChemoCentryx where he was involved in the discovery and clinical development of 7 novel immunology drugs in only 7 years. During his career, Dr. Powers has been an inventor on 75 US patents and has been responsible for the discovery of 17 compounds that have gone into clinical development.
Nigel Walker, PhD
SVP, Protein Therapeutics
Dr. Walker has a distinguished career in drug discovery with more than 35 years of experience in the pharmaceutical, biotechnology and chemical industries. Prior to joining Arcus, Dr. Walker was the Executive Director of Amgen’s Molecular Structure & Characterization division leading over 80 staff engaged in providing company-wide analytical & biophysical… support for all biologics and small molecule drug discovery programs. He also led Amgen’s structural classification of antibody inhibitors of PCSK9, including the marketed product Repatha®. Dr. Walker came to Amgen through their acquisition of Tularik, a company he joined as Director of Structural Biology in 1998. He started his industrial career at BASF AG in Germany.
Steve Young, PhD
SVP, Technology & Quantitative Biology
Dr. Young has held scientific, technical, and leadership roles across Europe and the US since 1993, most recently as VP of Technology at Flexus Biosciences and FLX Bio. He was the first scientist at Flexus and built the company’s biology and IT/informatics functions from the ground up…. Before working at Flexus, Dr. Young was an Executive Director at Amgen where he led 110 scientists across key technical functions including research automation and technology, materials management, HTS, bioassay technology, and target discovery/validation. He is currently on the Board of Directors of the Society for Laboratory Automation and Screening.